Compositions containing micronized tanaproget prepared by wet granulation
Compositions, preferably pharmaceutical compositions, containing micronized tanaproget, or pharmaceutically acceptable salt thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, butylated hydroxyanisole, povidone, and magnesium stearate, are provided. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic to disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake.
1. A method of treating endometriosis, said method comprising administering a composition to a patient in need thereof, said composition comprising:
(i) about 0.01 to about 25 mg of tanaproget, or a tautomer or pharmaceutically acceptable salt thereof,
(ii) about 65% to about 97% wt/wt of microcrystalline cellulose,
(iii) about 2 to about 7% wt/wt of croscarmellose sodium,
(iv) about 2% wt/wt of sodium lauryl sulfate,
(v) about 0.1 to about 2% wt/wt of povidone,
(vi) about 0.25% wt/wt of magnesium stearate, and
(vii) about 0.10% wt/wt of butylated hydroxyanisole.
2. A method of treating endometriosis, said method comprising administering a composition to a patient in need thereof, said composition comprising:
(i) about 0.05 to about 1 mg of tanaproget, or a tautomer or pharmaceutically acceptable salt thereof,
(ii) about 65% to about 97% wt/wt of microcrystalline cellulose,
(iii) about 2 to about 7% wt/wt of croscarmellose sodium,
(iv) about 2% wt/wt of sodium lauryl sulfate,
(v) about 0.1 to about 2% wt/wt of povidone,
(vi) about 0.25% wt/wt of magnesium stearate, and
(vii) about 0.10% wt/wt of butylated hydroxyanisole.
3. The method according to claim 2 , said composition comprising about 0.05 to about 0.3 mg of tanaproget.
4. The method according to claim 2 , said composition comprising about 0.05 mg of tanaproget.
5. The method according to claim 2 , said composition comprising about 0.075 mg of tanaproget.
6. The method according to claim 2 , said composition comprising about 0.1 mg of tanaproget.
7. The method according to claim 2 , said composition comprising about 0.15 mg of tanaproget.
8. The method according to claim 2 , said composition comprising about 0.2 mg of tanaproget.
9. The method according to claim 2 , said composition comprising about 0.3 mg of tanaproget.
10. A method of treating endometriosis, said method comprising administering a composition to a patient in need thereof, said composition comprising:
(i) about 0.01% to about 25% wt/wt of micronized tanaproget, or a tautomer or pharmaceutically acceptable salt thereof,
(ii) about 65% to about 97% wt/wt of microcrystalline cellulose,
(iii) about 2 to about 7% wt/wt of croscarmellose sodium,
(iv) about 2% wt/wt of sodium lauryl sulfate,
(v) about 0.1 to about 2% wt/wt of povidone,
(vi) about 0.25% wt/wt of magnesium stearate, and
(vii) about 0.10% wt/wt of butylated hydroxyanisole.
11. The method according to claim 10 , said composition further comprising water.
12. The method according to claim 10 , said composition comprising about 0.01% wt/wt of tanaproget.
13. The method according to claim 10 , said composition comprising about 0.10% wt/wt of tanaproget.
14. The method according to claim 10 , said composition comprising about 1% wt/wt of tanaproget.
15. The method according to claim 10 , comprising about 5% wt/wt of tanaproget.
16. The method according to claim 10 , said composition comprising about 25% wt/wt of tanaproget.
17. The method according to claim 10 , wherein the particles of said micronized tanaproget are less than about 10 μm.
18. The method according to claim 10 , wherein the particles of said composition are less than, or equal to, about 125 μm.
19. The method according to claim 10 , further comprising administering a second progesterone receptor agonist, estrogen receptor agonist, progesterone receptor antagonist, selective estrogen receptor modulator, or combinations thereof.
20. A method of treating uterine myometrial fibroids, benign prostatic hypertrophy, dysfunctional bleeding, uterine leiomyomata, or polycystic ovary syndrome, said method comprising administering a composition of claim 1 to a patient in need thereof, said composition comprising:
(i) about 0.01% to about 25% wt/wt of micronized tanaproget, or a tautomer or pharmaceutically acceptable salt thereof,
(ii) about 65% to about 97% wt/wt of microcrystalline cellulose,
(iii) about 2 to about 7% wt/wt of croscarmellose sodium,
(iv) about 2% wt/wt of sodium lauryl sulfate,
(v) about 0.1 to about 2% wt/wt of povidone,
(vi) about 0.25% wt/wt of magnesium stearate, and
(vii) about 0.10% wt/wt of butylated hydroxyanisole.
21. The method according to claim 20 , said composition further comprising water.
22. The method according to claim 20 , said composition comprising about 0.01% wt/wt of tanaproget.
23. The method according to claim 20 , said composition comprising about 0.10% wt/wt of tanaproget.
24. The method according to claim 20 , said composition comprising about 1% wt/wt of tanaproget.
25. The method according to claim 20 , comprising about 5% wt/wt of tanaproget.
26. The method according to claim 20 , said composition comprising about 25% wt/wt of tanaproget.
27. The method according to claim 20 , wherein the particles of said micronized tanaproget are less than about 10 μm.
28. The method according to claim 20 , wherein the particles of said composition are less than, or equal to, about 125 μm.
29. The method according to claim 20 , further comprising administering a second progesterone receptor agonist, estrogen receptor agonist, progesterone receptor antagonist, selective estrogen receptor modulator, or combinations thereof.